BRAF and melanoma: Until recently, it has been anticipated that B-RAF and N-RAS mutations result in an activation of the RAS/RAF/MEK/ERK signalling pathway, thus in a comparable cellular phenotype which would similarly influence the clinical outcome of melanoma patients.